Company Name : Boehringer Ingelheim

Friday, February 17, 2017 9:15AM IST (3:45AM GMT)

(BW)(BOEHRINGER-INGELHEIM)

US FDA Expands Approval of Tiotropium Respimat® for Maintenance Treatment of Asthma in Children


Tiotropium Respimat® (marketed as SPIRIVA® Respimat®) now approved in US as asthma maintenance treatment for people aged 6 years and older1FDA approval expands use of tiotropium Respimat® in the US to a broad age range of people across all asthma severitiesTiotropium Respimat® is currently NOT APPROVED for use in children and adolescents with asthma outside of the US


Ingelheim, Germany

Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) approved tiotropium Respimat® (marketed as SPIRIVA® Respimat®) for the long-term, once-daily maintenance treatment of people with asthma aged 6 years and older who continue to experience symptoms despite their other maintenance therapy – usually either inhaled corticosteroid (ICS) alone, or a combination of inhaled corticosteroids/long-acting beta agonists (ICS/LABA).1 This approval reflects the comprehensive tiotropium Respimat® paediatric clinical trial programme, involving 905 children aged 6-11 years, conducted by Boehringer Ingelheim.2,3,4

 

Tiotropium Respimat® is part of a class of medicines called long-acting muscarinic antagonists (LAMA) and is the only one of its kind approved for asthma. It works differently from other treatment options by complementing other maintenance therapies (usually ICS/LABA) to open the airways, which helps people breathe better and reduces asthma attacks, also known as exacerbations.

 

“This FDA approval expands the US indication for tiotropium Respimat® to a broad range of patients, including children, adolescents and adults in the US who may suffer from symptomatic asthma despite taking other maintenance therapies,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “The expansive paediatric programme within the comprehensive UniTinA-asthma® clinical trial programme, reflects the ongoing commitment of Boehringer Ingelheim to providing innovative solutions for children and adults living with asthma and other serious respiratory diseases.”

 

In the comprehensive, large-scale UniTinA-asthma® clinical trial programme, tiotropium Respimat® demonstrated proven efficacy and safety as an add-on therapy for children, adolescents and adults with asthma.1,5,6,7,8,9,10,11,12,13

 

Tiotropium Respimat® is delivered via Respimat®, the only inhaler that actively* delivers a propellant-free mist, meaning a person just needs to take a slow deep breath in for the medication to go deep into the lungs.14,15,16,17,18,19,20

 

Previously, in September 2015, tiotropium Respimat® was approved in the US for the long-term, once-daily, prescription maintenance treatment of asthma in people aged 12 and older.1 Tiotropium Respimat® was approved in the EU in 2014 as an add-on therapy for adults (aged 18 and older) with asthma.

 

For more information please visit http://www.boehringer-ingelheim.com/press-release/ASTHMA-FDA-Expanded_Approval_of_Tiotropium_Respimat®

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products varies from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

 

-----------------

 

SPIRIVA® Respimat® is currently NOT APPROVED for use in children and adolescents under 18 years of age in the EU. SPIRIVA® Respimat® has been approved for use in asthma in over 50 countries, including in the EU, U.S. and Japan. The label varies by country. Please refer to the local product information.

 

* Respimat® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation

 

 

 

 


Click here for Media Contact Details
CONTACTS : Boehringer Ingelheim Corporate Communications Media + PR Dr. Kristin Jakobs Phone: +49 6132 77 144553 Mobile: +49 1516 89 47444 Fax: +49 6132 77 6601 Email: press@boehringer-ingelheim.com

More News from Boehringer Ingelheim

16/02/2017 8:30AM

Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generation COPD treatments

Boehringer Ingelheim announced a collaboration with Weill Cornell Medicine to identify new treatment approaches for chronic obstructive pulmonary disease (COPD) in order to develop novel treatments that could possibly ...

11/02/2017 3:05PM

Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung

Efficacy and safety of afatinib plus pembrolizumab to be assessed in Phase II trial in patients with locally advanced or metastatic squamous cell carcinoma (SqCC) of the lung Afatinib is approved in patients with ...

27/01/2017 9:15PM

Jardiance® (empagliflozin) becomes first type 2 diabetes medicine in the EU to include cardiovascular death reduction data in label

This is the first time the European Commission approved the use of a diabetes treatment for its effect on both blood sugar control and cardiovascular (CV) events The CV data incorporated into the updated label are ...

Similar News

23/02/2017 3:45PM Image

Piramal Enterprises Limited and Ivanhoé Cambridge Announce Partnership to Invest in Residential Development in India

‘Piramal Enterprises Limited and Ivanhoé Cambridge Announce Partnership to Invest in Residential Development in India’.

No Image

22/02/2017 2:45PM Image

Bangalore-based Start-up, Cardiotrack, a Fast Growing Predictive Diagnostic Technology Platform for Cardiac Care, Strengthens its Footprint in Mexico and France

Bangalore-based start-up, Cardiotrack, which provides best-in-class predictive diagnosis for cardiovascular diseases, is strengthening its footprint in Mexico, France, and India as well. Cardiotrack, is a global name ...